Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent.

Journal of translational medicine - 19 Dec 2014

del Bufalo Francesca, Carai Andrea, Figà-Talamanca Lorenzo, Pettorini Benedetta, Mallucci Conor, Giangaspero Felice, Antonelli Manila, Badiali Manuela, Moi Loredana, Bianco Giuseppe, Cacchione Antonella, Locatelli Franco, Ferretti Elisabetta, Mastronuzzi Angela

Abstract excerpt

BACKGROUND: Ganglioglioma (GG) and pilocytic astrocytoma (PA) represent the most frequent low-grade gliomas (LGG) occurring in paediatric age. LGGs not amenable of complete resection (CR) represent a challenging subgroup where traditional treatments often fail. Activation of the MAP Kinase (MAPK) pathway caused by the BRAFV600E mutation or the KIAA1549-BRAF fusion has been reported in pediatric GG and PA,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ganglioglioma

Share to Indoles

Share to Magnetic Resonance Imaging

Share to Proto-Oncogene Proteins B-raf

Share to Sulfonamides

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 25524464
DOI: 10.1186/s12967-014-0356-1
PMCID: PMC4279809

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent.PMID 25524464Read ↗

Combination of BRAF and MEK inhibition in BRAF V600E mutant low-grade ganglioglioma.Semantic proximity Read ↗

A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation.Semantic proximity Read ↗

Pediatric brainstem gangliogliomas show BRAF(V600E) mutation in a high percentage of cases.Semantic proximity Read ↗

RAS/MAPK Pathway Alteration in Pediatric Low-Grade Glioma Complicated with Ventriculo-Peritoneal Shunt Related AscitesSemantic proximity Read ↗

Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy.Semantic proximity Read ↗

Resistance mechanisms in BRAFV600E paediatric high-grade glioma and current therapeutic approachesSemantic proximity Read ↗

Molecular Heterogeneity in BRAF-Mutant Gliomas: Diagnostic, Prognostic, and Therapeutic ImplicationsSemantic proximity Read ↗

Significant response to targeted therapy for Cervico-Medullary pediatric low grade glial tumors with BRAF V600E mutationSemantic proximity Read ↗

Clinical response to dabrafenib plus trametinib in a pediatric ganglioglioma with BRAF p.T599dup mutation.Semantic proximity Read ↗

Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas.Semantic proximity Read ↗

Clinical Relevance of BRAF V600E Mutation Status in Brain Tumors with a Focus on a Novel Management Algorithm.Semantic proximity Read ↗

Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.